lesabelimab + CDP1

This is a combination therapy consisting of lesabelimab (LDP), a human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and CDP1, a recombinant chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). CDP1 is developed as a biosimilar to cetuximab. The combination is designed to leverage the synergistic effects of immune checkpoint inhibition and targeted inhibition of the EGFR signaling pathway, which is frequently overexpressed in various epithelial tumors. Developed by Dragonboat Biopharmaceutical (a subsidiary of Guilin Sanjin Pharmaceutical), the regimen is currently undergoing Phase 1 clinical evaluation for advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, and several gynecological and squamous cell malignancies.

Other names

Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)LDP + CDP1